Perspective Therapeutics (CATX) Expected to Announce Earnings on Wednesday

Perspective Therapeutics (NYSEAMERICAN:CATX) is anticipated to issue its Q4 2025 results before the market opens on Wednesday, March 25th. Analysts expect the company to announce earnings of ($0.36) per share and revenue of $0.2320 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 16, 2026 at 4:00 PM ET.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.51) EPS for the quarter. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%.The business had revenue of $0.04 million for the quarter. On average, analysts expect Perspective Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Perspective Therapeutics Stock Down 4.7%

Shares of Perspective Therapeutics stock opened at $4.24 on Tuesday. Perspective Therapeutics has a 1 year low of $1.60 and a 1 year high of $6.16. The company has a quick ratio of 5.17, a current ratio of 5.17 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average price of $4.41 and a 200-day moving average price of $3.45.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on CATX shares. Piper Sandler started coverage on shares of Perspective Therapeutics in a research report on Thursday, February 19th. They set an “overweight” rating and a $16.00 price target for the company. B. Riley Financial lifted their price objective on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, March 18th. Royal Bank Of Canada dropped their target price on shares of Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 17th. Truist Financial set a $12.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, March 17th. Finally, BTIG Research restated a “buy” rating and set a $14.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $12.63.

Institutional Investors Weigh In On Perspective Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CATX. Geode Capital Management LLC lifted its holdings in shares of Perspective Therapeutics by 15.8% in the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock worth $4,758,000 after buying an additional 188,887 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Perspective Therapeutics by 118.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock worth $2,573,000 after acquiring an additional 405,612 shares during the period. Walleye Capital LLC increased its holdings in Perspective Therapeutics by 375.8% during the 2nd quarter. Walleye Capital LLC now owns 187,403 shares of the company’s stock worth $645,000 after acquiring an additional 148,013 shares during the period. Federated Hermes Inc. lifted its stake in Perspective Therapeutics by 44.4% in the 2nd quarter. Federated Hermes Inc. now owns 195,080 shares of the company’s stock worth $671,000 after purchasing an additional 60,019 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in Perspective Therapeutics by 8.5% in the 2nd quarter. Bank of America Corp DE now owns 327,500 shares of the company’s stock valued at $1,127,000 after purchasing an additional 25,697 shares during the period. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.